Overview

While bearing in mind that antiretroviral drugs (ARVs) have revolutionized the treatment for HIV and has been life-saving to millions, it doesn't remain an answer forever. ARVs are not very effective beyond the blood-brain barrier and a vast sanctuary of HIV infected cells in the microglia and astrocytes remains, causing HIV-associated neurocognitive disorder (HAND) and less frequently HIV associated dementia (HAD). Neurological inflammation of currently unknown mechanisms causing a subacute encephalitis, sometimes leading to progresssive multifocal leukodystrophy (PML) also requires further research.Immgenuity Inc. is a biotechnology research and development company championing the use of a therapeutic vaccine in the treatment of HIV. Immgenuity combines innovation and ingenuity to meet unmet medical needs in the treatment of HIV with a particular emphasis on neurological involvement.

Immgenuity's flagship product is a recombinant, live, attenuated therapeutic vaccine for the treatment and potential remission of AIDS and the HIV infection. Immgenuity's IMTV014 has shown a very high level of success in pre-clinical studies and pilot clinical trials. Further studies are in final planning stages in several countries where interest is extremely high.

Immgenuity has acquired several patents and intellectual property for IMTV014 across the globe and is anxious to start Phase I clinical trials. Immgenuity considers this invention to be a ground-breaking step forward in the fight against AIDS and HIV, particularly in neurological manifestations of HIV and as a part of structured therapeutic interruptions to achive a remission. Immgenuity plans to apply for and obtain several additiona patents as more data is obtained.

As ARV resistant strains of HIV emerge and as renal toxicity as well as other conditions such as lipodystrophy become common, a product like IMTV014 is sorely needed as a vehicle to immunologically excite the defenses against HIV, particularly in the highly conserved sanctuary regions such as the brain.